结缔组织病相关间质性肺疾病的治疗研究进展  

Progress in the treatment of connective tissue disease related interstitial lung disease

作　　者：赵娜[1] 陈立辉[1] 张玉柱[2] 夏光涛[1] ZHAO Na;CHEN Li-hui;ZHANG Yu-zhu;XIA Guang-tao(Department of Rheumatology and Immunology, Shandong Provincial Hospital, Shandong University, Ji＇nan 250021;Department of Anesthesiology, Central Hospital of ZiBo, ZiBo 255022, China)

机构地区：[1]山东大学附属省立医院风湿免疫科,济南250021 [2]淄博市中心医院麻醉科,淄博255022

出　　处：《世界临床药物》2018年第6期427-430,共4页World Clinical Drug

基　　金：山东省自然科学基金项目(编号:ZR2015HM082)

摘　　要：结缔组织病(CTD)患者合并间质性肺疾病(ILD)是导致患者死亡的重要原因之一,也是目前临床诊治CTD-ILD的难点之一。系统性硬化症相关间质性肺病(SSc-ILD)是常见的CTD-ILD,发生率较高。本文简要概述CTD-ILD的临床特征、诊断和治疗,以及抗纤维化药物治疗SSc-ILD的临床研究。Connective tissue disease（CTD） complicated with interstitial lung disease（ILD） is the important causes of CTD patients＇ death. However, the clinical diagnosis and treatment of connective tissue disease related interstitial lung disease（CTD-ILD） are still difficult. The systemic sclerosis associated interstitial lung disease（SSc-ILD） is a common CTD-ILD with a high incidence. This article gives a brief overview of the clinical features, diagnosis and treatment of CTDILD, as well as the clinical study of anti fibrosis drug therapy for SSc-ILD.

关 键 词：结缔组织病(CTD) 间质性肺疾病(ILD) 系统性硬化症相关间质性肺病(SSc-ILD) 吡非尼酮 

分 类 号：R563[医药卫生—呼吸系统] R593.2[医药卫生—内科学]